patients with bipolar disorder. This observational study used the PharMetrics medical claims database (commercially available from PharMetrics, Inc, under restricted license) to examine a cohort of 47,918 bipolar disorder patients with a minimum 1-year window of data before and after the index date of bipolar disorder diagnosis. Here, we examine suicide attempts for the n = 13,385 bipolar disorder patients who received AED monotherapy, defined for a 1-year period following the index episode as taking 1 AED but not lithium. Treatment with other medications was permitted. Since all participants were retained during the study time period, we compared suicide attempt rates 1 month before and after the initiation of AEDs by using a 2-sided McNemar test. Within the paired design, the odds ratio (also known as Mantel-Haenszel odds ratio) was calculated among the discordant pairs.
Results. Figure 1 gives both the number and the rate (per 1,000 person-years) of suicide attempts by time before and after AED initiation. The trend line is fairly flat with the exception of a large peak observed during the month before the start of AEDs. The suicide attempt rate during the month before AED initiation was significantly higher than the rate during the month after AED initiation (OR = 3.83, 95% CI, 2.55-5.94; P < .0001).
These data do not support the hypothesis that institution of AED pharmacotherapy is associated with an increase in the rate of suicide attempts in patients with bipolar disorder. Rather, they suggest that AED treatment is initiated in response to presence of episodes associated with increased risk for suicidal behavior. These findings comport with those of Simon and colleagues, 6 who found suicide attempts to be more frequent in the month prior to antidepressant prescription compared to afterward. Together, these 2 analyses underscore the importance of examining data before as well as after treatment initiation in studies using naturalistic data to understand drug effects on suicidal acts.
